Emerging Therapeutic Approaches for Amyotrophic Lateral Sclerosis (ALS)
Iranian Journal of Pharmaceutical Sciences,
Vol. 20 No. 4 (2024),
15 October 2024
,
Page 345- 362
https://doi.org/10.22037/ijps.v20i4.45154
Abstract
Motor neuron disease (MND) is a collection of degenerative neurological disorders that impact the motor neurons responsible for controlling involuntary muscular movements. Amyotrophic lateral sclerosis (ALS) is the predominant variant, affecting both the upper and lower motor neurons in the brain and spinal cord. As the disease progresses, these neurons deteriorate, leading to muscle weakness, wasting, and inability to regulate voluntary motions. ALS can impair speech, swallowing, and breathing, causing significant impairment over time. Additional types of motor neuron disease (MND) encompass primary lateral sclerosis (PLS), progressive muscular atrophy (PMA), and progressive bulbar palsy (PBP). These types exhibit variations in the location and severity of motor neuron involvement, but they all share the progressive degeneration of motor neurons. Treatment may involve medication, physical therapy, assistive equipment, and supportive care to manage symptoms and consequences over time. This review's primary aim is crucial for gaining a deeper understanding of the disease's fundamental causes and creating innovative therapies or interventions to enhance the outlook and quality of life for individuals suffering from MND.
- Neuron
- Disease
- Amyotrophic
- Lateral
- Sclerosis
- Progressive
- Atrophy
- Bulbar palsy
How to Cite
References
H. Sung, J. Ferlay, R.L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, F. Bray, Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, CA Cancer J. Clin. 71(3) (2021) 209-249.
NH. Matthews, W.Q. Li, A.A. Qureshi, M.A. Weinstock, E. Cho, Epidemiology of Melanoma, in: W.H. Ward, J.M. Farma (Eds.), Cutaneous Melanoma: Etiology and Therapy, Codon Publications The Authors., Brisbane (AU), 2017.
J.G. Einspahr, S.P. Stratton, G.T. Bowden, D.S. Alberts, Chemoprevention of human skin cancer, Crit. Rev. Oncol. Hematol. 41(3) (2002) 269-85.
D. Didona, G. Paolino, U. Bottoni, C. Cantisani, Non Melanoma Skin Cancer Pathogenesis Overview, Biomedicines 6(1) (2018).
S. Marlar, H.H. Jensen, F.H. Login, L.N. Nejsum, Aquaporin-3 in Cancer, Int J Mol Sci 18(10) (2017).
D.K. Yadav, S. Kumar, E.H. Choi, S. Chaudhary, M.H. Kim, Computational Modeling on Aquaporin-3 as Skin Cancer Target: A Virtual Screening Study, Front Chem 8 (2020) 250.
M. Hara-Chikuma, A.S. Verkman, Aquaporin-3 facilitates epidermal cell migration and proliferation during wound healing, J. Mol. Med. (Berl.) 86(2) (2008) 221-31.
Y. Sugiyama, Y. Ota, M. Hara, S. Inoue, Osmotic stress up-regulates aquaporin-3 gene expression in cultured human keratinocytes, Biochim Biophys Acta 1522(2) (2001) 82-8.
S.K. Agarwal, A. Gupta, Aquaporins: The renal water channels, Indian J. Nephrol. 18(3) (2008) 95-100.
C. Zhu, Z. Chen, Z. Jiang, Expression, Distribution and Role of Aquaporin Water Channels in Human and Animal Stomach and Intestines, Int J Mol Sci 17(9) (2016).
S.Y. Jung, D.C. Park, S.S. Kim, S.G. Yeo, Expression, Distribution and Role of Aquaporins in Various Rhinologic Conditions, Int J Mol Sci 21(16) (2020).
A.S. Verkman, J. Ruiz-Ederra, M.H. Levin, Functions of aquaporins in the eye, Prog. Retin. Eye Res. 27(4) (2008) 420-33.
13. WB Bollag, L. Aitkens, J. White, K.A. Hyndman, Aquaporin-3 in the epidermis: more than skin deep, Am. J. Physiol. Cell Physiol. 318(6) (2020) C1144-c1153.
R. Zwiech, A. Bruzda-Zwiech, E. Balcerczak, J. Szczepańska, A. Krygier, B. Małachowska, D. Michałek, D. Szmajda-Krygier, A potential link between AQP3 and SLC14A1 gene expression level and clinical parameters of maintenance hemodialysis patients, BMC Nephrol. 23(1) (2022) 297.
C.S. Moon, D. Moon, S.K. Kang, Aquaporins in Cancer Biology, Front. Oncol. 12 (2022) 782829.
Y.L. Liu, T. Matsuzaki, T. Nakazawa, S. Murata, N. Nakamura, T. Kondo, M. Iwashina, K. Mochizuki, T. Yamane, K. Takata, R. Katoh, Expression of aquaporin 3 (AQP3) in normal and neoplastic lung tissues, Hum. Pathol. 38(1) (2007) 171-8.
Y. Machida, Y. Ueda, M. Shimasaki, K. Sato, M. Sagawa, S. Katsuda, T. Sakuma, Relationship of aquaporin 1, 3, and 5 expression in lung cancer cells to cellular differentiation, invasive growth, and metastasis potential, Hum. Pathol. 42(5) (2011) 669-78.
A. Li, D. Lu, Y. Zhang, J. Li, Y. Fang, F. Li, J. Sun, Critical role of aquaporin-3 in epidermal growth factor-induced migration of colorectal carcinoma cells and its clinical significance, Oncol. Rep. 29(2) (2013) 535-40.
M. Kusayama, K. Wada, M. Nagata, S. Ishimoto, H. Takahashi, M. Yoneda, A. Nakajima, M. Okura, M. Kogo, Y. Kamisaki, Critical role of aquaporin 3 on growth of human esophageal and oral squamous cell carcinoma, Cancer Sci. 102(6) (2011) 1128-36.
X. Guo, T. Sun, M. Yang, Z. Li, Z. Li, Y. Gao, Prognostic value of combined aquaporin 3 and aquaporin 5 overexpression in hepatocellular carcinoma, Biomed Res Int 2013 (2013) 206525.
D. Niu, Y. Bai, Q. Yao, W. Hou, L. Zhou, X. Huang, C. Zhao, Expression and Significance of AQP3 in Cutaneous Lesions, Anal. Cell. Pathol. (Amst.) 2021 (2021) 7866471.
Y.T. Huang, J. Zhou, S. Shi, H.Y. Xu, F. Qu, D. Zhang, Y.D. Chen, J. Yang, H.F. Huang, J.Z. Sheng, Identification of Estrogen Response Element in Aquaporin-3 Gene that Mediates Estrogen-induced Cell Migration and Invasion in Estrogen Receptor-positive Breast Cancer, Sci. Rep. 5 (2015) 12484.
N. Yang, W. Xiao, X. Song, W. Wang, X. Dong, Recent Advances in Tumor Microenvironment Hydrogen Peroxide-Responsive Materials for Cancer Photodynamic Therapy, Nanomicro Lett 12(1) (2020) 15.
C. Prata, S. Hrelia, D. Fiorentini, Peroxiporins in Cancer, Int J Mol Sci 20(6) (2019).
Q. Wang, B. Lin, H. Wei, X. Wang, X. Nie, Y. Shi, AQP3 Promotes the Invasion and Metastasis in Cervical Cancer by Regulating NOX4-derived H(2)O(2) Activation of Syk/PI3K/Akt Signaling Axis, J. Cancer 15(4) (2024) 1124-1137.
H. Xu, Y. Xu, W. Zhang, L. Shen, L. Yang, Z. Xu, Aquaporin-3 positively regulates matrix metalloproteinases via PI3K/AKT signal pathway in human gastric carcinoma SGC7901 cells, J. Exp. Clin. Cancer Res. 30(1) (2011) 86.
A.S. Verkman, M. Hara-Chikuma, M.C. Papadopoulos, Aquaporins--new players in cancer biology, J. Mol. Med. (Berl.) 86(5) (2008) 523-9.
B. Aikman, A. de Almeida, S.M. Meier-Menches, A. Casini, Aquaporins in cancer development: opportunities for bioinorganic chemistry to contribute novel chemical probes and therapeutic agents, Metallomics 10(5) (2018) 696-712.
A. de Almeida, B.L. Oliveira, J.D.G. Correia, G. Soveral, A. Casini, Emerging protein targets for metal-based pharmaceutical agents: An update, Coord. Chem. Rev. 257(19) (2013) 2689-2704.
CM Niemietz, SD. Tyerman, New potent inhibitors of aquaporins: silver and gold compounds inhibit aquaporins of plant and human origin, FEBS Lett. 531(3) (2002) 443-7.
Martins AP, Marrone A, Ciancetta A, Galán Cobo A, Echevarría M, Moura TF, Re N, Casini A, Soveral G. Targeting aquaporin function: potent inhibition of aquaglyceroporin-3 by a gold-based compound. PLoS One. 2012;7(5):e37435.
A. Serna, A. Galán-Cobo, C. Rodrigues, I. Sánchez-Gomar, J.J. Toledo-Aral, T.F. Moura, A. Casini, G. Soveral, M. Echevarría, Functional inhibition of aquaporin-3 with a gold-based compound induces blockage of cell proliferation, J. Cell. Physiol. 229(11) (2014) 1787-801.
X. Liu, Q. Zhang, Z. Hong, D. Xu, Induction of heartwood formation in young Indian sandalwood (Santalum album L.) by gas elicitors, Front Plant Sci 13 (2022) 961391.
N.J. Khound, R.K. Bharali, Biosorption of fluoride from aqueous medium by Indian sandalwood (Santalum Album) leaf powder, Journal of Environmental Chemical Engineering 6(2) (2018) 1726-1735.
S. Santha, C. Dwivedi, Anticancer Effects of Sandalwood (Santalum album), Anticancer Res. 35(6) (2015) 3137-45.
R.L. Moy, C. Levenson, Sandalwood Album Oil as a Botanical Therapeutic in Dermatology, J. Clin. Aesthet. Dermatol. 10(10) (2017) 34-39.
C. Ortiz, L. Morales, M. Sastre, W.E. Haskins, J. Matta, Cytotoxicity and Genotoxicity Assessment of Sandalwood Essential Oil in Human Breast Cell Lines MCF-7 and MCF-10A, Evid. Based Complement. Alternat. Med. 2016 (2016) 3696232.
A. Bommareddy, J. Oberlin, K. Blankenhorn, S. Hughes, E. Mabry, A. Knopp, A. VanWert, C. Dwivedi, I. Pinkerton, L. Gutierrez, Alpha-santalol, a derivative of sandalwood oil prevents development of prostate cancer in TRAMP mice, Phytomedicine Plus 4(1) (2024) 100523.
K. Vermeulen, D.R. Van Bockstaele, Z.N. Berneman, The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer, Cell Prolif. 36(3) (2003) 131-49.
L. Li, X. Chen, H. Gu, The signaling involved in autophagy machinery in keratinocytes and therapeutic approaches for skin diseases, Oncotarget 7(31) (2016) 50682-50697.
X. Li, H.L. Xu, Y.X. Liu, N. An, S. Zhao, J.K. Bao, Autophagy modulation as a target for anticancer drug discovery, Acta Pharmacol. Sin. 34(5) (2013) 612-24.
42. S.E. Dickinson, E.R. Olson, C. Levenson, J. Janda, J.J. Rusche, D.S. Alberts, G.T. Bowden, A novel chemopreventive mechanism for a traditional medicine: East Indian sandalwood oil induces autophagy and cell death in proliferating keratinocytes, Arch. Biochem. Biophys. 558 (2014) 143-52.
S. Ijaz, N. Akhtar, M.S. Khan, A. Hameed, M. Irfan, M.A. Arshad, S. Ali, M. Asrar, Plant derived anticancer agents: A green approach towards skin cancers, Biomed. Pharmacother. 103 (2018) 1643-1651.
K. Singh, H. Maurya, P. Singh, P. Panda, AK Behera, A. Jamal, G. Eslavath, S. Mohapatra, H. Chauhan, D. Sharma, DISPEL: database for ascertaining the best medicinal plants to cure human diseases, Database (Oxford) 2023 (2023).
R.P. Vivek-Ananth, K. Mohanraj, A.K. Sahoo, A. Samal, IMPPAT 2.0: An Enhanced and Expanded Phytochemical Atlas of Indian Medicinal Plants, ACS Omega 8(9) (2023) 8827-8845.
46. T. Schwede, J. Kopp, N. Guex, M.C. Peitsch, SWISS-MODEL: An automated protein homology-modeling server, Nucleic Acids Res. 31(13) (2003) 3381-5.
G. Studer, G. Tauriello, S. Bienert, M. Biasini, N. Johner, T. Schwede, ProMod3-A versatile homology modelling toolbox, PLoS Comput. Biol. 17(1) (2021).
J. Xu, F. Jiao, B. Berger, A tree-decomposition approach to protein structure prediction, Proc IEEE Comput Syst Bioinform Conf (2005) 247-56.
G.G. Krivov, M.V. Shapovalov, R.L. Dunbrack, Jr., Improved prediction of protein side-chain conformations with SCWRL4, Proteins 77(4) (2009) 778-95.
P. Eastman, J. Swails, J.D. Chodera, R.T. McGibbon, Y. Zhao, K.A. Beauchamp, L.P. Wang, A.C. Simmonett, M.P. Harrigan, C.D. Stern, R.P. Wiewiora, B.R. Brooks, V.S. Pande, OpenMM 7: Rapid development of high performance algorithms for molecular dynamics, PLoS Comput. Biol. 13(7) (2017) e1005659.
A.D. Mackerell, Jr., M. Feig, C.L. Brooks, 3rd, Extending the treatment of backbone energetics in protein force fields: limitations of gas-phase quantum mechanics in reproducing protein conformational distributions in molecular dynamics simulations, J. Comput. Chem. 25(11) (2004) 1400-15.
V.B. Chen, W.B. Arendall, 3rd, J.J. Headd, D.A. Keedy, R.M. Immormino, G.J. Kapral, L.W. Murray, J.S. Richardson, D.C. Richardson, MolProbity: all-atom structure validation for macromolecular crystallography, Acta Crystallogr. D Biol. Crystallogr. 66(Pt 1) (2010) 12-21.
P. Benkert, M. Biasini, T. Schwede, Toward the estimation of the absolute quality of individual protein structure models, Bioinformatics 27(3) (2011) 343-50. https://doi.org/10.1093/bioinformatics/btq662.
E.F. Pettersen, T.D. Goddard, C.C. Huang, G.S. Couch, D.M. Greenblatt, E.C. Meng, T.E. Ferrin, UCSF Chimera--a visualization system for exploratory research and analysis, J. Comput. Chem. 25(13) (2004) 1605-12.
O. Trott, A.J. Olson, AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading, J. Comput. Chem. 31(2) (2010) 455-61.
S. Dallakyan, A.J. Olson, Small-molecule library screening by docking with PyRx, Methods Mol. Biol. 1263 (2015) 243-50.
Discovery Studio Modeling Environment, Release 4.5. 2021. BIOVIA, Dassault Systèmes, San Diego.
A. Daina, O. Michielin, V. Zoete, SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules, Sci. Rep. 7(1) (2017) 42717.
59. C.A. Lipinski, F. Lombardo, B.W. Dominy, P.J. Feeney, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Adv Drug Deliv Rev 46(1-3) (2001) 3-26.
D.A. Filimonov, A.A. Lagunin, T.A. Gloriozova, A.V. Rudik, D.S. Druzhilovskii, P.V. Pogodin, V.V. Poroikov, Prediction of the Biological Activity Spectra of Organic Compounds Using the Pass Online Web Resource, Chemistry of Heterocyclic Compounds 50(3) (2014) 444-457.
G. Xiong, Z. Wu, J. Yi, L. Fu, Z. Yang, C. Hsieh, M. Yin, X. Zeng, C. Wu, A. Lu, X. Chen, T. Hou, D. Cao, ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties, Nucleic Acids Res. 49(W1) (2021) W5-w14.
C. Oostenbrink, A. Villa, A.E. Mark, W.F. van Gunsteren, A biomolecular force field based on the free enthalpy of hydration and solvation: the GROMOS force-field parameter sets 53A5 and 53A6, J. Comput. Chem. 25(13) (2004) 1656-76.
M.J. Abraham, T. Murtola, R. Schulz, S. Pall, J.C. Smith, B. Hess, E. Lindahl, GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers, SoftwareX 1-2 (2015) 19-25.
Sever B, Ciftci H, DeMirci H, Sever H, Ocak F, Yulug B, Tateishi H, Tateishi T, Otsuka M, Fujita M, Başak AN. Comprehensive research on past and future therapeutic strategies devoted to treatment of amyotrophic lateral sclerosis. Int. J. Mol. Sci. (2022) 23(5): 2400.
Chavda VP, Patel C, Modh D, Ertas YN, Sonak SS, Munshi NK, Anand K, Soni A, Pande S. Therapeutic Approaches to Amyotrophic Lateral Sclerosis from the Lab to the Clinic. Current Drug Metabolism. (2022) 23(3): 200.
Pampalakis G, Angelis G, Zingkou E, Vekrellis K, Sotiropoulou G. A chemogenomic approach is required for effective treatment of amyotrophic lateral sclerosis. Clin. Transl. Med. (2022) 12(1): e657.
Feldman EL, Goutman SA, Petri S, Mazzini L, Savelieff MG, Shaw PJ, Sobue G. Amyotrophic lateral sclerosis. The Lancet. (2022) 400(10360):1363.
Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, Burrell JR, Zoing MC, Amyotrophic lateral sclerosis. The lancet. (2011) 377(9769): 942.
Masrori P, Van Damme P. Amyotrophic lateral sclerosis: a clinical review. Eur. J. Neurol. (2020) 27(10): 1918.
Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, Kalra S, Katz JS, Mitsumoto H, Rosenfeld J, Shoesmith C. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2009) 73(15): 1227.
Kasarskis EJ, Tandan R. Why is nutrition vital for advancing ALS care and clinical research? Amyotroph. Lateral Scler. Frontotemporal Degener. (2023): 20, 1.
Jaiswal MK. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. Med. Res. Rev. (2019) 39(2):733.
Blyufer A, Lhamo S, Tam C, Tariq I, Thavornwatanayong T, Mahajan SS. Riluzole: A neuroprotective drug with potential as a novel anti cancer agent. Int. J. Oncol. (2021) 59(5):1.
Jaiswal MK. Riluzole but not melatonin ameliorates acute motor neuron degeneration and moderately inhibits SOD1-mediated excitotoxicity induced disrupted mitochondrial Ca2+ signaling in amyotrophic lateral sclerosis. Front. Cell. Neurosci. (2017) 10: 295.
Writing Group; “Edaravone (MCI-186) ALS 19 Study Group- Safety and efficacy of edaravone in well-defined patients with amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled trial”, Lancet Neurol, (2017) 16(7): 505.
Romero-Gangonells E, Virgili-Casas MN, Povedano M, Barcelo MA. Clinical and demographical characteristics in a cohort of MND patients treated with riluzole. Differences between tablets and oral suspension. Amyotroph. Lateral Scler. Frontotemporal Degener. (2023) 24(5-6): 369.
Abe K, Itoyama Y, Sobue G, Tsuji S, Aoki M, Doyu M, Hamada C, Kondo K, Yoneoka T, Akimoto M, Yoshino H. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph. Lateral Scler. Frontotemporal Degener. (2014) 15(7-8): 610.
Spencer PS, Lagrange E, Palmer VS, Reis J, Steele JC, Román GC. Amyotrophic lateral sclerosis from genotoxins alone The Lancet Neurology, (2022) X 21(9):771.
Kasarskis EJ, Mendiondo MS, Matthews DE, Mitsumoto H, Tandan R, Simmons Z, Bromberg MB, Kryscio RJ. ALS Nutrition/NIPPV Study Group Estimating daily energy expenditure in individuals with amyotrophic lateral sclerosis. The Ame. J. Clin. Nutr. (2014) 99(4): 792.
Korner S, Sieniawski M, Kollewe K, Rath KJ, Krampfl K, Zapf A, Dengler R, Petri S. Speech therapy and communication device: impact on quality of life and mood in patients with amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Frontotemporal Degener. (2013) 14(1):20.
Brooks BR, Thisted RA, Appel SH, Bradley WG, Olney RK, Berg JE, Pope LE, Smith RA. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial”, Neurology (2004) 63(8):1364.
Finegan E, Chipika RH, Li Hi Shing S, Hardiman O, Bede P. Pathological crying and laughing in motor neuron disease: pathobiology, screening, intervention. Front. in Neurol. (2019) 10: 260.
Çoban M, Bilge U, Balseven H, Uysal H, Artut B. The economic evaluation of ALS care: quality and cost. Amyotroph. Lateral Scler. Frontotemporal Degener. (2023) 24(5-6): 502.
Weiss MD, Macklin EA, Simmons Z, Knox AS, Greenblatt DJ, Atassi N, Graves M, Parziale N, Salameh JS, Quinn C, Brown RH. A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression. Neurology (2016) 86(16): 1474.
Oskarsson B, Moore D, Mozaffar T, Ravits J, Wiedau‐Pazos M, Parziale N, Joyce NC, Mandeville R, Goyal N, Cudkowicz ME, Weiss M. Mexiletine for muscle cramps in amyotrophic lateral sclerosis: A randomized, double‐blind crossover trial. Muscle & nerve. (2018) 58(1):42.
Bedlack RS, Pastula DM, Hawes J, Heydt D. Open-label pilot trial of levetiracetam for cramps and spasticity in patients with motor neuron disease. Amyotrophic Lateral Sclerosis (2009) 10 (4): 210.
Borasio GD, Voltz R, Miller RG. Palliative care in amyotrophic lateral sclerosis. Neurologic clinics. (2001)19(4): 829.
Cudkowicz M, Genge A, Maragakis N, Petri S, van den Berg L, Aho VV, Sarapohja T, Kuoppamaki M, Garratt C, Al-Chalabi A, Kiernan M. Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet Neurology (2021) 20(10):821.
Chia R, Chio A, Traynor BJ. Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. The Lancet Neurology. (2018) 17(1): 94.
Dharmadasa T, Henderson RD, Talman PS, Macdonell RA, Mathers S, Schultz DW, Needham M, Zoing M, Vucic S, Kiernan MC. Motor neurone disease: progress and challenges. Med. J. Aust. (2017) 206 (8): 357.
Nolano M, Provitera V, Caporaso G, Fasolino I, Borreca I, Stancanelli A, Dubbioso R. Skin innervation across amyotrophic lateral sclerosis clinical stages: new prognostic biomarkers. Brain; a Journal of Neurology. (2024) 147(5): 1740-1750.
Lu L, Deng Y, Xu R. Current potential therapeutics of amyotrophic lateral sclerosis. Frontiers in Neurology. (2024) 15, 1402962.
- Abstract Viewed: 754 times
- IJPS_Volume 20_ Issue 4_Pages 345-362 Downloaded: 552 times